NCT07066527 Efficacy and Safety Analysis of Polylauric Alcohol More Stable Foam Versus Ordinary Foam in the Treatment of Head and Neck Venous Malformations
| NCT ID | NCT07066527 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qilu Hospital of Shandong University |
| Condition | Venous Malformation |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2022-06-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to explore the efficacy and safety of poly -LRB-cinnamyl alcohol) foam in the treatment of venous malformations of head and neck through a prospective randomized clinical trial, this trial may provide better treatment options and evidence for head and neck VMs.
Eligibility Criteria
Inclusion Criteria: 1. Age 14-60 years of age, sex unlimited (except pregnant women or those preparing for pregnancy) 2. Clinical diagnosis and imaging () were consistent with head and neck venous malformations 3. Participants volunteered to participate in the trial and signed an informed consent form. Exclusion Criteria: 1. People with serious systemic diseases, including heart disease, high blood pressure, diabetes, etc. , that are not under control. Heart Attack: 1. Recent frequent attacks of angina. 2. Recent history of myocardial infarction 3. Cardiac function grade iii-iv or with symptoms of sitting breathing, cyanosis, jugular venous distension, lower limb edema, etc. . 4. Heart disease complicated with hypertension 5. Type II or III Type II atrioventricular block, double bundle branch block, as syndrome, diabetes: blood sugar control in 8.88 mmol/L above, hypertension: after taking medicine blood pressure can not be controlled in the normal range namely systolic pressure below 140 mmhg, diastolic pressure below 90 mmhg) 2. Patients who are unable to follow up on time; 3. Persons who are mentally ill or have mental disorders; 4. The patient or his/her authorized person is unwilling to sign a written informed consent or comply with the protocol
Contact & Investigator
shaohua liu, Doctoral
PRINCIPAL INVESTIGATOR
Shandong University Qilu Hospital
Frequently Asked Questions
Who can join the NCT07066527 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 60 Years, studying Venous Malformation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07066527 currently recruiting?
Yes, NCT07066527 is actively recruiting participants. Contact the research team at lshabccba@126.com for enrollment information.
Where is the NCT07066527 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT07066527 clinical trial?
NCT07066527 is sponsored by Qilu Hospital of Shandong University. The principal investigator is shaohua liu, Doctoral at Shandong University Qilu Hospital. The trial plans to enroll 110 participants.